
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is a leader in the biotechnology industry with a strong portfolio of flagship drugs and a growing pipeline of new products. The company's recent quarterly performance beat expectations and shows a solid trend in prescription sales for multiple growth drivers. While there are some challenges ahead with upcoming patent expiries, Amgen's strong base business and ongoing business development initiatives provide stability. Investors are eagerly awaiting data releases for potential growth drivers, including the weight loss drug MariTide and the cardiovascular drug olpasiran. However, these drugs are not expected to reach the market within the next 12 months, and key phase III readouts for the oncology pipeline and I&I franchise are not expected until 2027/2028.
Bears say
Amgen is facing structural headwinds from the loss of exclusivity across key product franchises, leading to a decrease in revenue estimates and a slight decrease in the DCF-derived price target to $340. Additionally, the company's emerging products, such as Tepezza and Uplizna, offer potential long-term growth drivers but are largely unproven, creating uncertainty. While there are upside risks, such as strong data from pipeline assets and better-than-expected product performance, there are also downside risks, such as disappointing pipeline data and increased regulatory or pricing concerns. Therefore, the current risk/reward profile for Amgen is largely balanced, with limited visibility into its potential to offset revenue erosion pressures and sustain long-term growth.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares